Digestive Diseases
Immunology and Liver Disease
Innate and Adaptive Immune Responses in Hepatitis B Virus InfectionDas A. · Maini M.K.Division of Infection and Immunity, University College London, London, UK
|
|
Dig Dis 2010;28:126–132
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
* The final prices may differ from the prices shown due to specifics of VAT rules.
Article / Publication Details
First-Page Preview
Published online: May 07, 2010
Issue release date: May 2010
Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 0
ISSN: 0257-2753 (Print)
eISSN: 1421-9875 (Online)
For additional information: https://www.karger.com/DDI
Abstract
There is urgent need for novel immunotherapeutic strategies which, combined with current anti-viral therapy, may facilitate viral control and remove the need for long-term suppressive therapy in patients who have chronic hepatitis B virus (HBV) infection. To achieve this, it is critical to better understand mechanisms of innate and adaptive immune dysfunction and pathways of liver pathology. Here, we summarise recent advances pertaining to early immune events during acute HBV infection in an unusual cohort of patients sampled in the pre-clinical phase, and describe mechanisms of CD8 T cell attrition that apply to patients with chronic HBV infection. Furthermore, we describe a novel pathway of hepatocyte death mediated by innate natural killer (NK) cells. These pathways together provide novel pathogenic mechanisms for impaired viral control and liver damage during chronic HBV infection.
© 2010 S. Karger AG, Basel
Related Articles:
References
- Lavanchy D: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97–107.
- Lanier LL: Evolutionary struggles between NK cells and viruses. Nat Rev Immunol 2008;8:259–268.
- Dalod M, Hamilton T, Salomon R, et al: Dendritic cell responses to early murine cytomegalovirus infection: subset functional specialization and differential regulation by interferon alpha/beta. J Exp Med 2003;197:885–898.
- Tough DF, Borrow P, Sprent J: Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 1996;272:1947–1950.
- Wieland SF, Vega RG, Muller R, et al: Searching for interferon-induced genes that inhibit hepatitis B virus replication in transgenic mouse hepatocytes. J Virol 2003;77:1227–1236.
- Wieland SF, Guidotti LG, Chisari FV: Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol 2000;74:4165–4173.
- McClary H, Koch R, Chisari FV, Guidotti LG: Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J Virol 2000;74:2255–2264.
- Robek MD, Boyd BS, Chisari FV: Lambda interferon inhibits hepatitis B and C virus replication. J Virol 2005;79:3851–3854.
- Sommereyns C, Paul S, Staeheli P, Michiels T: IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008;4:e1000017.
- Kakimi K, Guidotti LG, Koezuka Y, Chisari FV: Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 2000;192:921–930.
- Wieland S, Thimme R, Purcell RH, Chisari FV: Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA 2004;101:6669–6674.
- Wieland SF, Chisari FV: Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol 2005;79:9369–9380.
- Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV: Viral clearance without destruction of infected cells during acute HBV infection. Science 1999;284:825–829.
- Webster GJ, Reignat S, Maini MK, et al: Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 2000;32:1117–1124.
- Dunn C, Peppa D, Khanna P, et al: Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 2009;137:1289–1300.
- Bertoletti A, Maini MK: Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection? Curr Opin Immunol 2000;12:403–408.
- Penna A, Chisari FV, Bertoletti A, et al: Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 1991;174:1565–1570.
- Bertoletti A, Ferrari C, Fiaccadori F, et al: HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci USA 1991;88:10445–10449.
- Maini MK, Boni C, Lee CK, et al: The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000;191:1269–1280.
- Webster GJ, Reignat S, Brown D, et al: Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 2004;78:5707–5719.
- Boni C, Fisicaro P, Valdatta C, et al: Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007;81:4215–4225.
- Lopes AR, Kellam P, Das A, et al: Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. J Clin Invest 2008;118:1835–1845.
- O’Connor L, Strasser A, O’Reilly LA, et al: Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J 1998;17:384–395.
- Bouillet P, Metcalf D, Huang DC, et al: Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999;286:1735–1738.
- Wojciechowski S, Jordan MB, Zhu Y, White J, Zajac AJ, Hildeman DA: Bim mediates apoptosis of CD127(lo) effector T cells and limits T cell memory. Eur J Immunol 2006;36:1694–1706.
- Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ: Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 2003;426:671–676.
- Sandalova E, Wei CH, Masucci MG, Levitsky V: Regulation of expression of Bcl-2 protein family member Bim by T cell receptor triggering. Proc Natl Acad Sci USA 2004;101:3011–3016.
- Sandalova E, Hislop AD, Levitsky V: T-cell receptor triggering differentially regulates Bim expression in human lymphocytes from healthy individuals and patients with infectious mononucleosis. Hum Immunol 2006;67:958–965.
- Bertolino P, Trescol-Biemont MC, Rabourdin-Combe C: Hepatocytes induce functional activation of naive CD8+ T lymphocytes but fail to promote survival. Eur J Immunol 1998;28:221–236.
- Morimoto J, Tan X, Teague RM, Ohlen C, Greenberg PD: Induction of tolerance in CD8+ T cells to a transgenic autoantigen expressed in the liver does not require cross-presentation. J Immunol 2007;178:6849–6860.
- Holz LE, Benseler V, Bowen DG, et al: Intrahepatic murine CD8 T-cell activation associates with a distinct phenotype leading to Bim-dependent death. Gastroenterology 2008;135:989–997.
-
Das A, Hoare M, Davies N, et al: Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J Exp Med 2008.
- Norris S, Collins C, Doherty DG, et al: Resident human hepatic lymphocytes are phenotypically different from circulating lymphocytes. J Hepatol 1998;28:84–90.
- Zimmerli SC, Harari A, Cellerai C, Vallelian F, Bart PA, Pantaleo G: HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc Natl Acad Sci USA 2005;102:7239–7244.
- Kakimi K, Lane TE, Wieland S, et al: Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. J Exp Med 2001;194:1755–1766.
- Dunn C, Brunetto M, Reynolds G, et al: Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med 2007;204:667–680.
- Krishnan S, Kiang JG, Fisher CU, et al: Increased caspase-3 expression and activity contribute to reduced CD3zeta expression in systemic lupus erythematosus T cells. J Immunol 2005;175:3417–3423.
- Tsuzaka K, Fukuhara I, Setoyama Y, et al: TCR zeta mRNA with an alternatively spliced 3′-untranslated region detected in systemic lupus erythematosus patients leads to the down-regulation of TCR zeta and TCR/CD3 complex. J Immunol 2003;171:2496–2503.
- Nakagomi H, Petersson M, Magnusson I, et al: Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 1993;53:5610–5612.
- Trimble LA, Lieberman J: Circulating CD8 T lymphocytes in human immunodeficiency virus-infected individuals have impaired function and downmodulate CD3 zeta, the signaling chain of the T-cell receptor complex. Blood 1998;91:585–594.
- Trimble LA, Shankar P, Patterson M, Daily JP, Lieberman J: Human immunodeficiency virus-specific circulating CD8 T lymphocytes have down-modulated CD3zeta and CD28, key signaling molecules for T-cell activation. J Virol 2000;74:7320–7330.
- Bronstein-Sitton N, Cohen-Daniel L, Vaknin I, et al: Sustained exposure to bacterial antigen induces interferon-gamma-dependent T cell receptor zeta down-regulation and impaired T cell function. Nat Immunol 2003;4:957–964.
- Rodriguez PC, Zea AH, DeSalvo J, et al: L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J Immunol 2003;171:1232–1239.
- Ando K, Moriyama T, Guidotti LG, et al: Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med 1993;178:1541–1554.
- Moriyama T, Guilhot S, Klopchin K, et al: Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science 1990;248:361–364.
- Sitia G, Isogawa M, Iannacone M, Campbell IL, Chisari FV, Guidotti LG: MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. J Clin Invest 2004;113:1158–1167.
- Kafrouni MI, Brown GR, Thiele DL: Virally infected hepatocytes are resistant to perforin-dependent CTL effector mechanisms. J Immunol 2001;167:1566–1574.
- Tay CH, Welsh RM: Distinct organ-dependent mechanisms for the control of murine cytomegalovirus infection by natural killer cells. J Virol 1997;71:267–275.
- Balkow S, Kersten A, Tran TT, et al: Concerted action of the FasL/Fas and perforin/granzyme A and B pathways is mandatory for the development of early viral hepatitis but not for recovery from viral infection. J Virol 2001;75:8781–8791.
- Galle PR, Hofmann WJ, Walczak H, et al: Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 1995;182:1223–1230.
- Wiley SR, Schooley K, Smolak PJ, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673–682.
- Sheridan JP, Marsters SA, Pitti RM, et al: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997;277:818–821.
- Zheng SJ, Wang P, Tsabary G, Chen YH: Critical roles of TRAIL in hepatic cell death and hepatic inflammation. J Clin Invest 2004;113:58–64.
Article / Publication Details
First-Page Preview
Published online: May 07, 2010
Issue release date: May 2010
Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 0
ISSN: 0257-2753 (Print)
eISSN: 1421-9875 (Online)
For additional information: https://www.karger.com/DDI
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
PubMed ID
